{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:56:34Z","timestamp":1783979794725,"version":"3.55.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["brachyjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brachytherapy"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.brachy.2023.05.002","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T18:56:16Z","timestamp":1686855376000},"page":"571-579","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["High-dose-rate brachytherapy as monotherapy versus as boost in unfavorable intermediate-risk localized prostate cancer: A matched-pair analysis"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1448-7983","authenticated-orcid":false,"given":"Benjamin D.","family":"Willen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3314-4196","authenticated-orcid":false,"given":"Kamran","family":"Salari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew H.","family":"Zureick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doyle","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Marvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirisha R.","family":"Nandalur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Krauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.brachy.2023.05.002_bib0001","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215582","article-title":"Long-term biochemical progression-free survival following brachytherapy for prostate cancer: further insight into the role of short-term androgen deprivation and intermediate risk group subclassification","volume":"14","author":"Matzkin","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.brachy.2023.05.002_bib0002","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrurol.2017.76","article-title":"The evolution of brachytherapy for prostate cancer","volume":"14","author":"Zaorsky","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.brachy.2023.05.002_bib0003","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1200\/JCO.2005.06.154","article-title":"Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate","volume":"23","author":"Sathya","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.brachy.2023.05.002_bib0004","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2012.01.007","article-title":"Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer","volume":"103","author":"Hoskin","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2023.05.002_bib0005","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D'Amico","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.brachy.2023.05.002_bib0006","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2023.05.002_bib0007","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.eururo.2013.03.033","article-title":"A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy","volume":"64","author":"Zumsteg","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.brachy.2023.05.002_bib0008","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.brachy.2023.05.002_bib0009","first-page":"51","article-title":"Prostate cancer, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"3","author":"Mohler","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.brachy.2023.05.002_bib0010","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ijrobp.2006.04.045","article-title":"High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: results of a phase I to II study","volume":"66","author":"Vargas","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2023.05.002_bib0011","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.ijrobp.2015.10.011","article-title":"Outcomes associated with 3 treatment schedules of high-dose-rate brachytherapy monotherapy for favorable-risk prostate cancer","volume":"94","author":"Jawad","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2023.05.002_bib0012","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1097\/01.ju.0000052720.62999.a9","article-title":"Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors","volume":"169","author":"Martinez","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2023.05.002_bib0013","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2023.05.002_bib0014","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ijrobp.2010.10.009","article-title":"Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer","volume":"82","author":"Mohammed","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2023.05.002_bib0015","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ijrobp.2009.10.008","article-title":"Confirmation of a low \u03b1\/\u03b2 ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics","volume":"79","author":"Proust-Lima","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2023.05.002_bib0016","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.canrad.2019.01.004","article-title":"Quel rapport alpha\/b\u00eata pour le cancer prostatique en 2019 ? [Which alpha\/beta ratio for prostate cancer in 2019?]","volume":"23","author":"Cosset","year":"2019","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.brachy.2023.05.002_bib0017","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.radonc.2020.03.033","article-title":"Rates of rectal toxicity in patients treated with high dose rate brachytherapy as monotherapy compared to dose-escalated external beam radiation therapy for localized prostate cancer","volume":"147","author":"Parzen","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2023.05.002_bib0018","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.ijrobp.2016.03.047","article-title":"Time course and accumulated risk of severe urinary adverse events after high- versus low-dose-rate prostate brachytherapy with or without external beam radiation therapy","volume":"95","author":"Tward","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2023.05.002_bib0019","first-page":"52","article-title":"PSA nadir predicts biochemical recurrence after external beam radiation therapy combined to high dose rate brachytherapy in the treatment of prostate cancer","volume":"10","author":"Coelho","year":"2022","journal-title":"Am J Clin Exp Urol"},{"key":"10.1016\/j.brachy.2023.05.002_bib0020","series-title":"Abstr Present Annu Meet Am Soc Radiat Oncol (ASTRO) San Antonio, TX","article-title":"Patient reported outcomes of NRG oncology\/RTOG 0232: a Phase III study comparing combined external beam radiation and transperineal interstitial permanent brachytherapy with brachytherapy alone in intermediate risk prostate cancer","author":"Bruner","year":"2018"},{"key":"10.1016\/j.brachy.2023.05.002_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers10090322","article-title":"High-dose-rate brachytherapy monotherapy versus image-guided intensity-modulated radiotherapy with helical tomotherapy for patients with localized prostate cancer","volume":"10","author":"Yamazaki","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.brachy.2023.05.002_bib0022","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.15083","article-title":"Effect of androgen deprivation on long-term outcomes of intermediate-risk prostate cancer stratified as favorable or unfavorable: a secondary analysis of the RTOG 9408 randomized clinical trial","volume":"3","author":"Zumsteg","year":"2020","journal-title":"JAMA Netw Open"}],"container-title":["Brachytherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472123000557?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472123000557?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:19:10Z","timestamp":1761531550000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538472123000557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1538472123000557"],"URL":"https:\/\/doi.org\/10.1016\/j.brachy.2023.05.002","relation":{},"ISSN":["1538-4721"],"issn-type":[{"value":"1538-4721","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-dose-rate brachytherapy as monotherapy versus as boost in unfavorable intermediate-risk localized prostate cancer: A matched-pair analysis","name":"articletitle","label":"Article Title"},{"value":"Brachytherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brachy.2023.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}